Liquidia (NASDAQ:LQDA) Insider Sells $791,345.06 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 21,142 shares of the stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $791,345.06. Following the completion of the sale, the insider owned 176,883 shares in the company, valued at $6,620,730.69. This represents a 10.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Rajeev Saggar also recently made the following trade(s):

• On Wednesday, November 5th, Rajeev Saggar sold 71,381 shares of Liquidia stock. The stock was sold at an average price of $27.00, for a total value of $1,927,287.00.

Liquidia Price Performance

LQDA stock traded up $1.49 on Tuesday, reaching $38.09. The company had a trading volume of 2,055,159 shares, compared to its average volume of 2,814,845. The company’s fifty day moving average is $31.94 and its 200 day moving average is $25.40. The company has a market cap of $3.31 billion, a P/E ratio of -26.45, a PEG ratio of 1.19 and a beta of 0.48. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20. Liquidia Corporation has a 1 year low of $11.26 and a 1 year high of $39.29.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative return on equity of 296.78% and a negative net margin of 176.04%.The company had revenue of $54.34 million during the quarter, compared to the consensus estimate of $18.86 million. The business’s revenue was up 1106.7% compared to the same quarter last year. On average, research analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current year.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Liquidia by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after purchasing an additional 1,700 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of Liquidia by 10.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock worth $12,703,000 after buying an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Liquidia by 15.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock worth $1,796,000 after buying an additional 16,022 shares during the period. Rhumbline Advisers raised its position in shares of Liquidia by 6.0% in the 1st quarter. Rhumbline Advisers now owns 85,463 shares of the company’s stock worth $1,261,000 after buying an additional 4,811 shares during the period. Finally, Ballentine Partners LLC boosted its holdings in Liquidia by 10.2% in the second quarter. Ballentine Partners LLC now owns 12,139 shares of the company’s stock valued at $151,000 after acquiring an additional 1,119 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined 18.1% to 10,709,682 shares as of Dec. 31 (about 17.6% of shares were sold short) and the days-to-cover was ~11.6. Fewer active shorts can reduce downside pressure and may have contributed to the stock moving higher. (Market data entry)
• Neutral Sentiment: January short-interest data shows 0 shares as of Jan. 12 — this is almost certainly a reporting or data glitch rather than a real liquidation of all short positions. Investors should monitor the next short-interest report for a corrected figure. (Market data entry)
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average $37.43 (≈$2.49M); his stake decreased ~6.03%. This large insider sale may be seen as a negative signal by some investors. SEC Filing
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 (≈$1.38M); his holding fell ~9.52%. SEC Filing
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 (≈$1.02M); his holding fell ~4.50%. SEC Filing
• Negative Sentiment: Other insiders (including Rajeev Saggar, Jason Adair, Scott Moomaw, Sarah Krepp, CAO Dana Boyle) also executed sales on Jan. 12 at ~$37.43 per share, each reducing positions between ~6–11.7%. These combined sales represent significant insider liquidity taken at current prices. Rajeev Saggar SEC Filing Dana Boyle SEC Filing Jason Adair SEC Filing Scott Moomaw SEC Filing Sarah Krepp SEC Filing

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Wells Fargo & Company began coverage on shares of Liquidia in a research note on Monday, October 20th. They set an “overweight” rating and a $31.00 price target on the stock. Needham & Company LLC upped their price objective on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Raymond James Financial restated a “strong-buy” rating and set a $47.00 target price on shares of Liquidia in a research report on Tuesday, November 4th. Wall Street Zen raised shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, HC Wainwright increased their price target on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.67.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).